Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

David L. Porter, Selina M. Luger, Kathleen M. Duffy, Edward A. Stadtmauer, Ginna Laport, Stephen J. Schuster, Gregory Orloff, Donald Tsai, Kevin McDaid, Addya Kathakali, Debra G.B. Leonard, Joseph H. Antin

Research output: Contribution to journalArticle

Abstract

Allogeneic donor leukocytes can be used after nonmyeloablative conditioning to exploit their graft-versus-tumor (GVT) activity in the setting of reduced conditioning-regimen toxicity. This approach may be particularly useful for patients who relapse after autologous stem cell transplantation (SCT). However, GVT activity, toxicity, and ability to establish mixed chimerism may differ in patients who were heavily pretreated prior to SCT compared with patients treated earlier in the course of their disease. We have performed a series of studies of nonmyeloablative allogeneic transplantation and present data on the subset of 14 patients treated for relapse after autologous SCT: 4 patients received no conditioning and unstimulated donor leukocyte infusions (DLI), 10 patients received conditioning with fludarabine and cyclophosphamide followed by unstimulated or granulocyte-colony-stimulating factor (G-CSF)-stimulated allogeneic peripheral blood stem cells (PBSCs), 4 patients received no graft-versus-host disease (GVHD) prophylaxis, and 10 patients received cyclosporine GVHD prophylaxis. All but 1 patient had sustained donor chimerism at least 30 days after allogeneic cell therapy (ACT), and 8 patients had more than 80% donor chimerism after ACT. Acute GVHD developed in 11 patients (grade III-IV, n=6). Aplasia was more frequent in the patients receiving unstimulated PBSCs, despite the development of mixed chimerism. There were 6 complete responses and 4 partial responses; response was independent of conditioning and growth-factor stimulation of the donor graft. Five patients died of treatment-related causes and 4 patients died from progressive disease. Four patients remained alive 27 to 194 weeks (median, 66 weeks) after ACT. Prior autologous SCT may define a subset of patients at particularly high risk for GVHD and other toxicity after ACT. However, these data show that ACT with either DLI or G-CSF-stimulated blood cells results in direct GVT activity in some patients with Hodgkin's disease, myeloma, and non-Hodgkin's lymphoma, even after relapse from autologous SCT. Most patients developed donor chimerism with minimal conditioning. Alternative prophylactic regimens that control GVHD while maintaining GVT are needed to improve outcomes in these heavily pretreated patients.

Original languageEnglish (US)
Pages (from-to)230-238
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume7
Issue number4
DOIs
StatePublished - Jan 1 2001

Keywords

  • Allogeneic cell therapy
  • Graft-versus-tumor activity
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this

    Porter, D. L., Luger, S. M., Duffy, K. M., Stadtmauer, E. A., Laport, G., Schuster, S. J., Orloff, G., Tsai, D., McDaid, K., Kathakali, A., Leonard, D. G. B., & Antin, J. H. (2001). Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biology of Blood and Marrow Transplantation, 7(4), 230-238. https://doi.org/10.1053/bbmt.2001.v7.pm11349810